The Autopsy / Case File · Chronic Disease Progression
The Under-55 Liver
Cirrhosis used to have a face: a man in his sixties, decades into heavy drinking, the disease finally catching up with him. A June 2025 study of two decades of CDC death records says that face is out of date. The fastest-growing share of liver disease deaths in America now belongs to women, and to adults who haven't turned 55.
Cirrhosis mortality more than doubled in the United States between 1999 and 2022, reaching 9.5 deaths per 100,000 people. Among women, the rate more than tripled, to nearly 6 per 100,000. Alcohol-associated liver disease deaths were essentially flat through 2006, climbed at 3.5 percent a year through 2018, then accelerated to nearly 9 percent a year after that. Among Native American and Alaska Native adults, cirrhosis mortality hit 33 deaths per 100,000 in 2022 alone — the highest of any group measured. The dataset comes from CDC WONDER; the analysis, led by a Stanford University hepatologist, was published in JAMA Network Open.
Join the discussion →
Cirrhosis kills slowly and then all at once. The liver absorbs injury for years — from alcohol, from viral hepatitis, from the fat buildup of metabolic disease — replacing dead tissue with scar tissue in a process called fibrosis. A scarred liver can still mostly function, which is why the disease is so often invisible until it isn't: until the scarring is so extensive that blood can no longer move through the organ properly, fluid backs up into the abdomen, toxins the liver used to filter start reaching the brain, and a person who felt merely tired a year earlier is now jaundiced, disoriented, and bleeding internally from vessels that ruptured under pressure they were never built to hold. That collapse point is what a death certificate usually captures. The mortality data captures something else: how much earlier, and in whom, American livers are now reaching it.
A Rate That Left Its Old Shape
The study, published in JAMA Network Open in June 2025 under the senior authorship of Stanford University School of Medicine hepatologist Robert Wong, drew on CDC WONDER's underlying-cause-of-death data from 1999 through 2022. The topline number is stark enough on its own: cirrhosis-related mortality across the U.S. adult population more than doubled over those 23 years, from roughly 4 deaths per 100,000 people to 9.5. But the aggregate rate was never the point of the analysis — the demographic breakdown was. Among men, the rate reached 13.3 per 100,000 by 2022, still the higher of the two sexes in absolute terms. Among women, it reached nearly 6 per 100,000 — more than triple where it stood in 1999, a growth rate outpacing men's by a wide margin and eroding a gap that used to be one of the most consistent patterns in American liver disease.
Age told a similar story. The years from 2018 to 2022 alone saw cirrhosis mortality climb 9 percent annually — more than double the 3.5 percent annual pace recorded from 2006 to 2018 — and alcohol-associated hepatitis, the acute inflammatory condition that can precede or accompany cirrhosis, showed its sharpest average annual increase, 8.4 percent, in the years from 2007 to 2022 specifically among adults age 25 to 44. Among women specifically, cirrhosis mortality climbed 8.32 percent a year from 2011 to 2022, according to the same underlying CDC WONDER series. None of this is the epidemiological profile textbooks describe. Liver disease mortality was supposed to be a story about accumulation over a long lifetime, concentrated in men in their fifties and sixties. What the data shows instead is a disease compressing its timeline and shifting who it reaches first.
What Changed in the Liver, Not Just the Bottle
The mechanism researchers point to isn't a mystery ingredient — it's a change in drinking pattern layered on top of biology that makes some people's livers more vulnerable than others'. Alcohol-associated liver disease progresses through recognized stages: first steatosis, simple fatty buildup in liver cells; then, with continued exposure, steatohepatitis, in which the fat triggers inflammation; then fibrosis and cirrhosis as the inflamed tissue scars over; and finally, in the worst cases, decompensation — the point at which a chronically damaged liver can no longer compensate for its own scarring and acute failure sets in. Research on the disease's biology, including a 2023 study in Nature Communications, has identified binge-pattern drinking specifically, not just total volume consumed, as one of the strongest predictors of who develops severe alcohol-related liver disease — a pattern more common among younger drinkers than the steady, lower-volume daily drinking pattern associated with older generations' liver disease. Genetic risk factors and the presence of diabetes compound that risk further, and researchers have identified measurable biomarkers — phosphatidylethanol and ethyl glucuronide among them — that can now detect recent heavy drinking with more precision than a doctor's questionnaire ever could, part of a push toward screening people for liver risk before symptoms appear rather than after.
Layered on top of the biology is a documented behavioral shift. Multiple epidemiological reviews, including a 2024 analysis in the Journal of Studies on Alcohol and Drugs literature, have tracked a narrowing gap between men's and women's drinking patterns over the past two decades, with younger women's binge-drinking rates rising toward parity with men's even as the underlying medical evidence shows women's livers are more vulnerable to alcohol's toxic effects than men's at equivalent exposure levels — smaller average body size and different alcohol-metabolizing enzyme activity mean the same volume of alcohol does more damage per pound of liver tissue. Then came the pandemic. Multiple studies tracking alcohol sales and self-reported consumption during 2020 found significant increases in heavy and binge drinking, concentrated among women managing new caregiving and economic stress — and the liver-mortality data shows the acceleration in ALD deaths beginning right around that period and never fully receding.
The disease didn't change. The population reaching its terminal stage did — younger, and increasingly female, arriving at the same scarred, failing organ that used to take a man most of a lifetime to build.
A Disparity Inside the Disparity
No single demographic shift in the data is starker than the one among Native American and Alaska Native adults. Alcohol-associated hepatitis mortality in that population more than doubled between 2010 and 2022, reaching 3.4 deaths per 100,000 — already the highest rate of any racial or ethnic group tracked. Cirrhosis mortality specifically hit 33 deaths per 100,000 in 2022, a figure that dwarfs the roughly 9.5-per-100,000 national average and reflects an 18 percent annual rate of increase in the years leading up to it. Public health researchers studying American Indian and Alaska Native health disparities have repeatedly traced elevated liver disease burden in this population back to the same structural drivers behind most of the group's other mortality gaps: disproportionate poverty, historical trauma, geographic isolation from specialty hepatology care, and — specific to liver disease — documented underinvestment in Indian Health Service treatment infrastructure relative to need. The JAMA Network Open analysis didn't set out to explain why the gap exists; it simply confirmed, with two decades of federal mortality data, that it's the widest disparity inside an already-worsening national trend.
A Screening Problem Nobody's Solved
Part of what makes the shift dangerous is that cirrhosis remains, in its early and middle stages, a disease with almost no symptoms a patient would notice or a primary care visit would catch without specifically looking for it. Unlike a cholesterol panel or a blood pressure cuff, there's no routine test built into an annual physical that screens for liver fibrosis the way there is for cardiovascular risk — a gap researchers studying the alcohol-associated liver disease surge have specifically flagged as an opportunity being missed at scale, given that biomarker-based and imaging-based fibrosis screening tools already exist and are accurate enough for population-level use. The biomarkers described above — PEth and ethyl glucuronide for alcohol exposure, alongside noninvasive elastography imaging that can measure liver stiffness without a biopsy — are all technically available today. What's missing is the systematic decision to screen high-risk groups, including the younger women the mortality data now identifies as a genuinely high-risk population, before the first sign of decompensation rather than after.
That gap matters because cirrhosis, caught early enough, is one of the more interruptible chronic diseases in American medicine. Stopping alcohol use before cirrhosis reaches its decompensated stage can halt or even partially reverse fibrosis in many patients — a biological window that simply doesn't exist for most of the leading causes of chronic disease death. The tragedy embedded in the mortality data isn't that liver disease became more lethal as a disease process; the pathology is the same fibrosis-to-cirrhosis pathway it's always been. It's that a population the healthcare system wasn't watching for it — women, adults in their thirties and forties, patients whose drinking pattern reads as "occasional binge" rather than "daily heavy use" on a standard intake questionnaire — is now dying of it at rates that, twenty years ago, belonged almost exclusively to a different generation and a different sex.
And Then You're Dead
Nobody becomes a liver disease statistic on the night of the binge that finally does the damage. It happens years earlier and years later at once — years earlier, in the drinking pattern a screening test could have flagged; years later, in the emergency room where jaundice and confusion finally look like what they are. The under-55 liver isn't a different organ. It's the same one, reached by a different person, faster than the data used to expect.
That's it. That's the whole thing.
Sources
- Cirrhosis mortality more than doubling since 1999 (to 9.5 per 100,000 in 2022), the more-than-tripled rate among women (to nearly 6 per 100,000, versus 13.3 for men), the acceleration to a 9% annual increase from 2018-2022 (versus 3.5% from 2006-2018), the 8.4% annual increase in alcohol-associated hepatitis mortality among ages 25-44 (2007-2022), the 8.32%-a-year rise in women's cirrhosis mortality (2011-2022), and the Native American/Alaska Native figures (hepatitis mortality more than doubling 2010-2022 to 3.4 per 100,000; cirrhosis mortality reaching 33 per 100,000 in 2022) — Odenwald MA et al., CDC WONDER underlying-cause-of-death analysis, JAMA Network Open, June 2025, senior author Robert Wong (Stanford University School of Medicine), as reported by STAT News, "Women, young adults, and Native people hit hard by rapid increase in alcohol liver deaths, study finds," June 11, 2025, and U.S. News & World Report, June 13, 2025
- The steatosis-to-steatohepatitis-to-fibrosis-to-cirrhosis-to-decompensation disease progression pathway and the role of noninvasive fibrosis screening and biomarkers (phosphatidylethanol, ethyl glucuronide) in high-risk-population screening — Merck Manual Professional Edition, "Alcohol-Related Liver Disease"; peer-reviewed alcohol biomarker research literature
- Binge-pattern alcohol consumption, genetic risk, and diabetes as the strongest predictors of severe alcohol-related liver disease, and the lipid-pathway disease mechanism — "Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease," Nature Communications, 2023
- The narrowing gap between men's and women's drinking patterns, women's greater physiological vulnerability to alcohol's hepatotoxic effects at equivalent exposure, and the COVID-19 pandemic's association with increased heavy/binge drinking concentrated among women — epidemiology of alcohol-associated liver disease literature, including "Epidemiology of Alcohol-Associated Liver Disease Including Increasing Burden in Young Adults and Females Especially Since Covid-19 Pandemic," Clinics in Liver Disease/ScienceDirect, 2024
- Structural drivers behind elevated Native American/Alaska Native liver disease mortality (poverty, geographic isolation from hepatology specialty care, Indian Health Service resource gaps) — Indian Health Service and peer-reviewed American Indian/Alaska Native health disparities literature
- Photo: "Cirrhosis of the liver," Medical Photographic Library, St Bartholomew's Hospital Archives & Museum, circa 1893–1912, via Wellcome Collection and Wikimedia Commons (CC BY 4.0)
Comments
Loading…